New drug and high-tech scans aim to calm thyroid eye disease
NCT ID NCT07423013
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called teprotumumab N01 in 50 adults with thyroid eye disease, an autoimmune condition that causes bulging eyes and discomfort. Participants receive the drug and are monitored with special PET and MRI scans to see if inflammation and eye changes improve. The main goal is to check how many people respond well after 24 weeks of treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Third Hospital
RECRUITINGBeijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted antibody calm thyroid eye disease?
- Could a cholesterol drug shrink eye muscle swelling in thyroid eye disease?
- Can an experimental drug reduce eye bulging in thyroid eye disease?
- Can a new drug ease bulging eyes in thyroid disease?
- New drug IBI3031 enters first human trial for thyroid eye disease
- New hope for thyroid eye disease: drug shows promise in Steroid-Resistant patients